Karmanos Cancer Institute | Strategic Alliance Partners

March 01, 2024

The new process checking system makes sure the right drugs are dispensed, improving patient safety.

February 20, 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

February 13, 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

January 24, 2024

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

September 08, 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

September 08, 2023

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

August 22, 2023

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

June 01, 2023

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

May 26, 2023

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

May 24, 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

May 24, 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

May 23, 2023

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

May 17, 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

May 17, 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

May 12, 2023

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

May 11, 2023

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

May 10, 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

May 10, 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

May 09, 2023

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

May 03, 2023

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.